The Elephant in the Room: Personal Use of Psychedelics Among Psychedelic Researchers
- PMID: 40046568
- PMCID: PMC11665260
- DOI: 10.1089/psymed.2023.29002.psh
The Elephant in the Room: Personal Use of Psychedelics Among Psychedelic Researchers
Conflict of interest statement
P.S.H. was previously in a paid advisory relationship with Silo Pharma and is currently in paid advisory relationships with the following organizations regarding the development of psychedelics and related compounds: Bright Minds Biosciences Ltd., Eleusis Benefit Corporation, Journey Colab Corporation, and Reset Pharmaceuticals, Inc. C.D.N. is a venture partner with Palo Santo, founder of 2A Biosciences, and a board member of the Heffter Research Institute.No funding was received for this article.
References
-
- Pagán AF, Lex C, Soares JC, et al. Medical students' attitudes and beliefs toward psilocybin: Does terminology and Personal experience with psychedelics matter? Psychedelic Med 2023;1:130–138.
-
- Herrmann Z, Levin AW, Cole SP, et al. Psychedelic use among psychiatric medication prescribers: Effects on well-being, depression, anxiety, and associations with patterns of use, reported harms, and transformative mental states. Psychedelic Med 2023;1:139–149.
-
- Aday JS, Skiles Z, Eaton N, et al. Personal psychedelic use is common among a sample of psychedelic therapists: Implications for research and practice. Psychedelic Med 2023;1:27–37.
-
- Osmond H. A review of the clinical effects of psychotomimetic agents. Ann N Y Acad Sci 1957;66:418–434. - PubMed
-
- Hofmann A. LSD: My Problem Child. Oxford University Press: Oxford, UK; 2013.
Publication types
LinkOut - more resources
Full Text Sources